Randomized Trial of Lapatinib Versus Placebo Added to Paclitaxel in the Treatment of Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancer - Concepedia

Concepedia

Publication | Closed Access

Randomized Trial of Lapatinib Versus Placebo Added to Paclitaxel in the Treatment of Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancer

139

Citations

19

References

2013

Year

Zhongzhen Guan, Binghe Xu, Michelle DeSilvio, Zhenzhou Shen, Wichit Arpornwirat, Zhongsheng Tong, Vicharn Lorvidhaya, Zefei Jiang, Junlan Yang, Wai Lim Leung,

Journal of Clinical Oncology

Abstract

This trial demonstrated that lapatinib combined with paclitaxel offers a significant and clinically meaningful survival advantage over paclitaxel alone in patients with HER2-positive MBC.

References

	Year	Citations

Page 1